Interim Clinical Study Results, Leadership Appointments, and Earnings Release Schedules - Analyst Notes on Merck, Magellan, ABIOMED, CONMED, and Greatbatch
PR Newswire - Tue Apr 15, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Magellan Health Services Inc. (NASDAQ: MGLN), ABIOMED, Inc. (NASDAQ: ABMD), CONMED Corporation (NASDAQ: CNMD), and Greatbatch, Inc. (NYSE: GB). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1143-100free
Balanced View on Greatbatch - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 9:10AM CDT
GB expects to grow through its efforts to develop innovative medical devices and build a healthy product pipeline
Four Apple Suppliers To Watch As IPhone 6 Launch Approaches
at The Street - Wed Apr 02, 3:24PM CDT
Chris Lau, Kapitall: AAPL isn't the only play to take advantage of the iPhone 6. These Apple suppliers are worth [...]
Greatbatch, Inc. to Host Q1 2014 Earnings Conference Call
GlobeNewswire - Mon Mar 31, 3:05PM CDT
Greatbatch, Inc. (NYSE:GB) announced today that it will host a conference call on Wednesday, April 30, 2014 at 5:00 p.m. E. T. to discuss its financial results for the first quarter 2014 ended April 4, 2014.
Medical Device Manufacturing Services Outsourcing Report 2014-2018 with Accellent, Creganna-Tactx Medical, Greatbatch, Flextronics Dominating
M2 - Thu Mar 13, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9v4tlj/global_medical) has announced the addition of the "Global Medical Device Manufacturing Services Outsourcing Market 2014-2018" report to their offering. Outsourcing of medical device manufacturing services to emerging countries is a growing trend in the market. By outsourcing, leading medical devices companies not only take advantage of reduced costs but also position themselves to better serve the local markets of emerging countries. Reduced cost of labor, a high level of technical expertise, and funding from governments for R&D investment to accelerate new product development in emerging countries such as China, India, Malaysia, Mexico, and Brazil have made them the most favored destinations for outsourcing manufacturing services. Hence, outsourcing to emerging countries is expected to drive the Global Medical Device Manufacturing Services Outsourcing market during the forecast period. According to the report, one of the main drivers in this market is the advancements in healthcare technologies, which is causing the development of more complex medical devices contributing to the growth of the market. Further, the report states that one of the major challenges in the market is stringent regulatory guidelines that need to be adhered to by outsourcing services providers for quality control and meet environmental requirements. The key vendors dominating this market space are: - Accellent Inc. - Creganna-Tactx Medical - Greatbatch Inc. - Flextronics International Ltd. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Services 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/9v...al_medical
Greatbatch, Inc. Issues Voluntary Field Corrective Action for Standard Offset Cup Impactor
Business Wire - Tue Mar 11, 11:07AM CDT
On January 29, 2014, Greatbatch, Inc. initiated a voluntary field corrective action for all Standard Offset Cup Impactors after an internal review determined that the sterilization recommendation in the Instructions for Use for the product did not meet requirements for sterility assurance, which has the potential to result in surgical infection. No incidents have been reported during clinical use of the product, nor have there been any reported adverse events.
Greatbatch Q4 Earnings Lag by a Penny - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 12:20PM CST
Net revenues in the quarter improved 11.0% (13% on an organic constant currency basis) to $176.6 million, which was almost in line with the Zacks Consensus Estimate of $176.0 million
Research and Markets: Concise Analysis of the International Food Emulsifiers Market Report
Business Wire - Tue Feb 25, 6:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/434qhg/food_emulsifiers) has announced the addition of the "Concise Analysis of the International Food Emulsifiers Market Report" report to their offering.
Greatbatch, Inc. Reports 2013 Fourth Quarter and Full Year Results
Business Wire - Mon Feb 24, 3:10PM CST
Greatbatch, Inc. (NYSE:GB), today announced results for its fourth quarter and full-year ended January 3, 2014 highlighted by 5% constant currency organic revenue growth for the full year 2013; 12% year over year improvement in adjusted operating income; and 19% improvement in adjusted diluted EPS over 2012.
Research and Markets: 2014 Strategies for the Hepatitis Markers Diagnostic Testing Market
Business Wire - Fri Feb 14, 6:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xmb9dv/2014_strategies) has announced the addition of the "2014 Strategies for the Hepatitis Markers Diagnostic Testing Market" report to their offering.
Greatbatch Has Returned 18.8% Since SmarTrend Recommendation (GB)
Comtex SmarTrend(R) - Mon Feb 03, 9:55AM CST
SmarTrend identified an Uptrend for Greatbatch (NYSE:GB) on October 16th, 2013 at $35.46. In approximately 4 months, Greatbatch has returned 18.77% as of today's recent price of $42.11.
Greatbatch, Inc. to Host 2013 Earnings Conference Call
GlobeNewswire - Mon Jan 27, 8:43AM CST
Greatbatch, Inc. (NYSE:GB) announced today that it will host a conference call on Tuesday; February 25, 2014 at 8:30 a.m. E. T. to discuss its financial results for the year ended January 3, 2014.
Roundtable Top Picks for the Week of Jan. 20th - Video Blog
Panel Of Zacks Experts - Zacks Investment Research - Mon Jan 20, 3:43PM CST
Ideas for Chemicals, Financials and Medical Devices. Stocks covered include PPG Industries (PPG), Waddell & Reed (WDR) and Greatbatch Inc. (GB).
Greatbatch Shares Up 25.5% Since SmarTrend's Buy Recommendation (GB)
Comtex SmarTrend(R) - Fri Jan 17, 4:55PM CST
SmarTrend identified an Uptrend for Greatbatch (NYSE:GB) on October 16th, 2013 at $35.46. In approximately 3 months, Greatbatch has returned 25.51% as of today's recent price of $44.50.
Greatbatch, Inc. to Present at the 32nd Annual JP Morgan Healthcare Conference
Business Wire - Fri Jan 03, 12:58PM CST
Greatbatch, Inc. NYSE: (GB) announced today that Thomas J. Hook, president and CEO, will present at the JP Morgan Healthcare conference on January 16, 2014 at 11:30 a.m. PT.
22.5% Return Seen to Date on SmarTrend Greatbatch Call (GB)
Comtex SmarTrend(R) - Fri Jan 03, 9:44AM CST
SmarTrend identified an Uptrend for Greatbatch (NYSE:GB) on October 16th, 2013 at $35.46. In approximately 3 months, Greatbatch has returned 22.46% as of today's recent price of $43.42.
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu Jan 02, 3:23PM CST
The broad-based S&P 500 finished 2013 exactly as it began, on a high note with yet another record close, pushing the index up 30% for the year and sending 819 companies to a new 52-week high compared to just 71 new lows. For skeptics like me,...
Shares of GB Up 22.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Dec 27, 9:21AM CST
SmarTrend identified an Uptrend for Greatbatch (NYSE:GB) on October 16th, 2013 at $35.46. In approximately 2 months, Greatbatch has returned 22.87% as of today's recent price of $43.56.
Addition to Indices, and Stock Price Movements - Research Report on ACADIA Pharmaceuticals, InterMune, Tandem Diabetes Care, Nektar Therapeutics and Greatbatch
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD), InterMune Inc. (NASDAQ: ITMN), Tandem Diabetes Care Inc (NASDAQ: TNDM), Nektar Therapeutics (NASDAQ: NKTR), and Greatbatch, Inc. (NYSE: GB). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.